Bank of America Corp DE Sells 9,611 Shares of Artivion, Inc. (NYSE:AORT)

Bank of America Corp DE decreased its position in Artivion, Inc. (NYSE:AORT) by 2.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 404,006 shares of the company’s stock after selling 9,611 shares during the quarter. Bank of America Corp DE owned 0.96% of Artivion worth $11,551,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its position in Artivion by 9.5% in the 4th quarter. BNP Paribas Financial Markets now owns 31,298 shares of the company’s stock worth $895,000 after buying an additional 2,724 shares during the last quarter. Northern Trust Corp lifted its position in Artivion by 10.0% in the 4th quarter. Northern Trust Corp now owns 463,250 shares of the company’s stock worth $13,244,000 after buying an additional 42,170 shares during the last quarter. Tudor Investment Corp ET AL lifted its position in Artivion by 23.0% in the 4th quarter. Tudor Investment Corp ET AL now owns 177,062 shares of the company’s stock worth $5,062,000 after buying an additional 33,098 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in Artivion in the 4th quarter worth approximately $699,000. Finally, Lord Abbett & CO. LLC lifted its position in Artivion by 40.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 306,702 shares of the company’s stock worth $8,769,000 after buying an additional 88,902 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

Insider Activity

In other news, SVP Marshall S. Stanton sold 10,548 shares of the business’s stock in a transaction that occurred on Friday, May 9th. The stock was sold at an average price of $29.13, for a total transaction of $307,263.24. Following the transaction, the senior vice president now directly owns 105,332 shares of the company’s stock, valued at approximately $3,068,321.16. The trade was a 9.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO James P. Mackin sold 42,156 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $1,151,280.36. Following the completion of the sale, the chief executive officer now directly owns 663,882 shares in the company, valued at approximately $18,130,617.42. The trade was a 5.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 111,273 shares of company stock valued at $2,951,340. Company insiders own 7.60% of the company’s stock.

Artivion Stock Performance

Shares of AORT stock opened at $28.41 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $32.33. The stock has a 50 day moving average price of $25.05 and a two-hundred day moving average price of $27.36. The company has a market capitalization of $1.21 billion, a P/E ratio of -1,420.25 and a beta of 1.54.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $98.98 million during the quarter, compared to the consensus estimate of $94.81 million. Analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Citizens Jmp upgraded Artivion to a “strong-buy” rating in a research report on Tuesday, May 6th. Stifel Nicolaus lowered their price objective on Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday, February 25th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price objective on shares of Artivion in a research report on Tuesday, May 6th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Artivion has an average rating of “Buy” and an average price target of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.